In vivo dissolution: Predominant factor affecting the bioavailability of rifampicin in its solid oral dosage forms

Clinical Research and Regulatory Affairs

Volumn 25, Issue 1, 2008, Pages 1-12

  Ashokraj, Yasvanth ^a   Kaur, Kanwal Jit ^a   Singh, Inderjit ^a   Kohli, Gunjan ^a   Bhade, Shantaram Ramdoss ^a   Varma, Manthena ^a   Agrawal, Shrutidevi ^a   Panchagnula, Ramesh ^a,b  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

^b PFIZER INC   (United States)

Author keywords

Bioavailability Bioequivalence; Dissolution; Fixed Dose Combination; In Vivo; Pharmacokinetics; Rifampicin

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG PENETRATION; DRUG SOLUBILITY; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; POWDER; STOMACH EMPTYING; TABLET FORMULATION; TUBERCULOSIS;

EID: 40149110954     PISSN: 10601333     EISSN: 15322521     Source Type: Journal    
DOI: 10.1080/10601330701885041     Document Type: Article

References (28)

1. Anonymous. The promise and reality of fixed-dose combinations with rifampicin. A joint statement of the International Union Against Tuberculosis and Lung Disease and the Tuberculosis Program of World Health Organization. Tuberc Lung Dis. 1994;75:180-181.
2. Veron LJ, Blanc LJ, Suchi M, Raviglione MC. DOTS expansion: will we reach the 2005 targets? Int J Tuberc Lung Dis. 2004;8:139-146.
3. Moulding T, Dutt AK, Reichman LB. Fixed dose combinations of anti-tuberculosis medications to prevent drug resistance. Ann Intern Med. 1995;122:951-954.
4. Grosset J. The sterilizing value of rifampicin and pyrazinamide in experimental short course chemotherapy. Tubercle. 1978;59:287-297.
5. Dickson JM, Mitchison DA. Experimental models to explain the high sterilizing activity of rifampicin in the chemotherapy of tuberculosis. Am Rev Respir Dis. 1981;123:367-371.
6. Blomberg B, Fourie B. Fixed dose combination drugs for tuberculosis. Appliaction in standardized treatment regimens. Drugs. 2003;63:535-553.
7. Telenti A, Iseman M. Drug resistant tuberculosis. What do we do now? Drugs. 2000; 59:171-179.
8. Burman WJ, Gallicano K, Peloquin CA. Comparaticve pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clin Pharmacokinetic. 2001;40:327-341.
9. Peloqiun CA. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs. 2002; 62:2169-2183.
10. Nitti V, Virgilio R, Patricolo MR, Juliano A. Pharmacokinetic study of intravenous rifampicin. Chemotherapy. 1977;21:1-6.
11. Mannisto P. Absorption of rifampicin from various preparations and pharmaceutic forms. Clin Pharmacol Ther. 1977;21:370-374.
12. Agrawal S, Singh I, Kaur KJ, Bhade SR, Kaul CL, Panchagnula R. Bioequivalence trials of rifampicin containing formulations: extrinsic and intrinsic factors in the absorption of rifampicin. Pharmacol Res. 2004;50:317-327.
13. Panchagnula R, Agrawal S, Ashokraj Y et al. Fixed dose combinations for tuberculosis: lessons learned from a clinical, formulation and regulatory perspective. Meth Find Exp Clin Pharmacol. 2004;26:703-721.
14. Shishoo CJ, Shah SA, Rathod IS, Savale SS, Vora MJ. Impaired bioavailability of rifampicin in presence of isoniazid from fixed dose combination (FDC) formulation. Int J Pharm. 2001;228:53-67.
15. Agrawal S, Panchagnula R. Implications of biopharmaceutics and pharmacokinetics of rifampicin in variable bioavailability from solid oral dosage forms. Biopharm Drug Dispos. 2005;26:321-334.
16. Amidon GL, Lennernas H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12:413-420.
17. Fourie B, Pillai G, McIlleron H, Smith P, Panchagnula R, Ellard G. Establishing the bioequivalence of rifampicin in fixed dose formulations containing isoniazid with or without pyrazinamide and/ or ethambutol compared to single drug reference preparations administered in loose combination (Model Protocol). World Health Organization; 1999:WHO/CDS/TB/99. 274.
18. Panchagnula R, Sood A, Sharda N, Kaur KJ, Kaul CL. Analysis of rifampicin and its main metabolite in presence of pyrazinamide and isoniazid in plasma and urine samples by HPLC method. J Pharm Biomed Anal. 1999;18:1505-1522.
19. Agrawal S, Kaul CL, Panchagnula R. Bioequivalence of isoniazid in two drug fixed dose combination and in a single drug dosage form. Pharmazie. 2001;56:636-639.
20. Martinez MN, Amidon GL. A mechanistic approach to understanding the factors affecting drug absorption: a review of fundamentals. J Clin Pharmacol. 2002;42:620-643.
21. Panchagnula R, Thomas NS. Biopharmaceutics and pharmacokinetics in drug research. Int J Pharm. 2000;201:131-150.
22. Lindenberg M, Kopp S, Dressman JB. Classification of orally administered drugs on the World Health Organization Model list of Essential Medicines according to the biopharmaceutics classification system. Eur J Pharm Biopharm. 2004;58(2):265-278.
23. United States Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for industry: dissolution testing of immediate release solid oral dosage forms. Silver Spring, MD:FDA; 1997.
24. Avdeef A. Physicochemical profiling (solubility, permeability and charge state). Curr Top Med Chem. 2001;1:277-351.
25. Dressman JB, Berardi RR, Dermentzoglou LC, Russell TL, Schmaltz SP, Barnett JL, Jarvenpaa K. Upper gastrointestinal pH in young, healthy men and women. Pharm Res. 1990;7:756-761.
26. Washington N, Lamont G. Wilson CG, Washington C, Withington R. The effect of high and low fat meals on the absorption of rifampicin from the gastro intestinal tract in volunteer subjects. Int J Pharm. 1994;108:125-131.
27. Keberle H. Physico-chemical factors of drugs affecting absorption, distribution and excretion. Acta Pharmacologica. 1970; (Suppl 3):30-47.
28. Khalil SAH, El-Khordagui LK, El-Gholmy ZA. Effect of antacids on oral absorption of rifampicin. Int J Pharm. 1984;20:99-106.